Another study has demonstrated that RES completely blocks HIV infection at a low micromolar dose in resting CD4+ T cells [17], demonstrating it as a potential adjuvant in anti-HIV therapy, especially in CNS reservoirs [18]. Here, CD4 is linked to HIV infectious disease.